A paper co-authored by Paidion CEO Dr. Barry Mangum was presented at the Hot Topics in Neonatology conference, December 6 – 9 in Washington, DC, an event that annually gathers more than 1000 neonatologists and perinatologists. The poster “Risk Assessment Based on In Vitro Testing to Evaluate Compatibility of Recombinant IGF-1/IGFBP-3 with Intravenous Medications Commonly Administered in the Neonatal Environment” summarized results from a study sponsored by Shire, a global innovator in specialty pharmaceuticals. The study’s objective was to assess the risk of compatibility of recombinant IGF-1/IGFBP-3 with medicines routinely given intravenously to preterm infants in the NICU. To see the poster, go to http://www.shirecongressposters.com/uploads/279238.pdf.
Type and hit enter